The Novavax coronavirus vaccine could be cleared by regulators for use in multiple countries, including the U.S., within the next three months, the company’s CEO said Monday.
Novavax has filed for emergency approval with 10 different regulatory agencies, Stanley Erck told CNBC. It’s currently available for use in 170 countries, he added.
“I expect in the next 90 days we could have all 10 of them,” Erck said.
The company delivered its final data to the U.S. Food and Drug Administration on New Year’s Eve. It has yet to file the full application for emergency-use authorization, but will do so shortly and expects a decision from American regulators in February.
Erck didn’t name the other regulatory agencies, but according to the company’s website, it has applied for approval in Japan, the United Arab Emirates, Singapore, New Zealand, Canada, Australia, South Africa and the United Kingdom.
Several other health agencies across the globe have already approved the vaccine.